Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF


Haas S., Camm A. J. , Bassand J., Angchaisuksiri P., Cools F., Corbalan R., ...Daha Fazla

AMERICAN HEART JOURNAL, cilt.213, ss.35-46, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 213
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.ahj.2019.03.013
  • Dergi Adı: AMERICAN HEART JOURNAL
  • Sayfa Sayıları: ss.35-46

Özet

Introduction A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) was to document changes in treatment practice for patients with newly diagnosed atrial fibrillation during an era when non-vitamin K antagonist oral anticoagulants (NOACs) were becoming more widely adopted. In these analyses, the key factors which determined the choice between NOACs and vitamin K antagonists (VKAs) are explored.